Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal Dissection
Consistent with clinical trial data, the findings in this study support PR as a strong predictor of survival in this patient population. Studies investigating the de-escalation of surgical and systemic treatment based on PR as well as biomarkers of patients who can achieve a pCR after monotherapy alone are warranted.
Authors
- Isabella C. Glitza Oliva (ORCID: https://orcid.org/0000-0002-4530-7765)
- Anthony Lucci (ORCID: https://orcid.org/0000-0003-4039-174X)
- Roi Weiser (ORCID: https://orcid.org/0000-0002-4522-6404)
- Sarah B. Fisher (ORCID: https://orcid.org/0000-0002-6881-2633)
- Joshua Herb (ORCID: https://orcid.org/0000-0002-0503-3739)
- Jeffrey E. Gershenwald (ORCID: https://orcid.org/0000-0003-4519-5369)
- Alexandra Ikeguchi
- Michael K. Wong
- Victor G. Prieto
- Hussein A. Tawbi
- Jennifer McQuade
- Carlos A. Torres-Cabala
- Rodabe N. Amaria
- Jennifer Wargo
- Roland L. Bassett
- Ashley M. Holder
- Michael A. Davies
- Merrick I. Ross
- Adi K. Diab
- Sapna P. Patel
Institutions
- Roswell Park Comprehensive Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Colorado Boulder (US)
Publication Details
- Journal
- Annals of Surgical Oncology
- Published
- 2026-03-16
- DOI
- https://doi.org/10.1245/s10434-026-19130-1
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Texas MD Anderson Cancer Center